Enzo Biochem PE Ratio 2006-2021 | ENZ

Current and historical p/e ratio for Enzo Biochem (ENZ) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Enzo Biochem PE ratio as of January 27, 2022 is 19.88.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Enzo Biochem PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-28 3.19 19.94
2021-10-31 3.44 $0.16 21.50
2021-07-31 3.26 $0.17 19.18
2021-04-30 3.07 $0.03 102.33
2021-01-31 2.82 $-0.22 0.00
2020-10-31 1.82 $-0.43 0.00
2020-07-31 2.38 $-0.60 0.00
2020-04-30 3.02 $-0.64 0.00
2020-01-31 2.51 $0.04 62.75
2019-10-31 3.16 $0.02 158.00
2019-07-31 3.91 $0.05 78.20
2019-04-30 3.47 $0.04 86.75
2019-01-31 3.76 $-0.49 0.00
2018-10-31 3.32 $-0.33 0.00
2018-07-31 4.42 $-0.21 0.00
2018-04-30 6.00 $-0.09 0.00
2018-01-31 7.36 $-0.03 0.00
2017-10-31 9.85 $-0.03 0.00
2017-07-31 10.85 $-0.05 0.00
2017-04-30 8.80 $0.72 12.22
2017-01-31 6.68 $0.67 9.97
2016-10-31 6.10 $0.84 7.26
2016-07-31 6.97 $0.97 7.19
2016-04-30 4.98 $0.38 13.11
2016-01-31 4.74 $0.37 12.81
2015-10-31 3.72 $0.13 28.62
2015-07-31 3.00 $-0.05 0.00
2015-04-30 2.80 $-0.30 0.00
2015-01-31 3.15 $-0.25 0.00
2014-10-31 5.22 $-0.25 0.00
2014-07-31 4.80 $-0.24 0.00
2014-04-30 4.20 $-0.25 0.00
2014-01-31 2.81 $-0.39 0.00
2013-10-31 2.49 $-0.44 0.00
2013-07-31 2.18 $-0.46 0.00
2013-04-30 2.24 $-1.07 0.00
2013-01-31 2.89 $-1.01 0.00
2012-10-31 2.00 $-0.98 0.00
2012-07-31 1.50 $-1.01 0.00
2012-04-30 2.74 $-0.43 0.00
2012-01-31 2.55 $-0.39 0.00
2011-10-31 2.86 $-0.43 0.00
2011-07-31 3.84 $-0.34 0.00
2011-04-30 3.99 $-0.38 0.00
2011-01-31 4.96 $-0.45 0.00
2010-10-31 4.31 $-0.57 0.00
2010-07-31 4.60 $-0.59 0.00
2010-04-30 5.97 $-0.58 0.00
2010-01-31 4.74 $-0.57 0.00
2009-10-31 5.51 $-0.50 0.00
2009-07-31 5.10 $-0.62 0.00
2009-04-30 4.10 $-0.57 0.00
2009-01-31 4.89 $-0.52 0.00
2008-10-31 5.77 $-0.43 0.00
2008-07-31 14.21 $-0.29 0.00
2008-04-30 8.18 $-0.29 0.00
2008-01-31 9.36 $-0.33 0.00
2007-10-31 12.11 $-0.36 0.00
2007-07-31 12.78 $-0.37 0.00
2007-04-30 16.81 $-0.42 0.00
2007-01-31 14.84 $-0.43 0.00
2006-10-31 14.30 $-0.43 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.154B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00